Almonzer Al-Qiami

Dr. Almonzer Al-Qiami

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
ERElena Cecilia Rosca
Elena Cecilia Rosca
Almonzer Al-QiamiAlmonzer Al-Qiami
Almonzer Al-Qiami
ACAmalia Cornea
Amalia Cornea
MSMihaela Simu
Mihaela Simu
Background: Parsonage–Turner syndrome (PTS) is an inflammatory condition of the brachial plexus, with more than half of patients presenting a trigger, such as infection or vaccination. Our objective was to synthesize the clinical and paraclinical features, therapeutic responses, and outcomes of PTS post-COVID-19 vaccination. Methods: We systematically reviewed two databases (LitCOVID and the WHO database on COVID-19) up to January 2024 following a published protocol (OSF registries). Results: We included 59 cases. PTS occurred more frequently in males (61.1% mRNA group, 83.3% viral vector group). Patients in the mRNA group were younger (41.7% between 41 and 50 years vs. 38.9% between 61 and 70 years). Most cases had sudden pain within two weeks. Unilateral PTS was present in 94.4% of mRNA and all viral vector-vaccinated cases. Symptoms included pain (97.1% and 92.3%, respectively), usually followed within two weeks by motor deficits (97.2% and 94.1%, respectively), amyotrophy (30% and 81.8%, respectively), paresthesia (50% and 27.3%, respectively), and sensory loss (33.3% and 38.5%, respectively). Viral vector vaccine recipients had nerve involvement outside the brachial plexus. Ancillary investigations revealed CSF albuminocytological dissociation (33.3% and 100%, respectively) and ipsilateral axillary lymphadenopathy. Two PTS cases worsened after the second mRNA dose, and another recurred after influenza vaccination. One patient well tolerated the second dose of the viral vector vaccine, but symptoms reemerged in another. Conclusions: Current evidence suggests PTS may occur after all COVID-19 vaccine types, with some subgroup differences. Also, PTS might recur with subsequent similar or unrelated vaccines.

5 August 2024 in Cerebrovascular Diseases
Verified
Journal Article
Open access
PDF file
AHAli Hammed
Ali Hammed
Almonzer Al-QiamiAlmonzer Al-Qiami
Almonzer Al-Qiami
AAAhmad Alzawahreh
Ahmad Alzawahreh
JRJosef Rosenbauer
Josef Rosenbauer
ENEman Ayman Nada
Eman Ayman Nada
CTChristian Tanislav
Christian Tanislav
Introduction: The treatment of acute ischemic stroke due to large artery vessel occlusion experienced a dramatic development within the last decade. This meta-analysis investigates the effectiveness of bridging therapy (BT) versus mechanical thrombectomy (MT) alone in treating acute ischemic stroke. Methods: Two independent reviewers assessed two-arm clinical trials from Scopus, PubMed, Web of Science, and the Cochrane Library up to January 2024. Data extraction and quality were evaluated using the ROBINS-2 tool. Our primary outcomes were improvement in NIHSS scores and 90-day modified Rankin Scale (mRS) score. Results: This meta-analysis, which included 2,638 participants from 8 randomized controlled trials, found that BT resulted in a greater improvement in NIHSS scores from baseline compared to endovascular treatment alone (mean difference [MD] 0.96, 95% confidence interval [CI]: [0.73–1.20], p < 0.00001). Additionally, BT group achieved successful recanalization more frequently before and after thrombectomy. Thrombectomy alone hat a shorter time from stroke onset to groin puncture compared to BT (MD 9.91, 95% CI: [4.31–15.52], p = 0.005). Functional outcomes, mortality rates, symptomatic intracerebral hemorrhage rates, and long-term recovery metrics, such as Barthel index and modified Rankin Scale scores, were comparable between both treatment approaches. Conclusion: BT is superior to endovascular treatment alone based on NIHSS score improvement and successful reperfusion rates before and after thrombectomy. Despite MT alone demonstrating a shorter time from stroke onset to groin puncture (MD of 9.91 min), it did not contribute to greater NIHSS improvement at 24 h and 7 days. Further trials with larger sample sizes are warranted to enhance precision in clinical guidance.

1 January 2024 in Pain Research and Management
Verified
Journal Article
Open access
EKErnest Kissi Kontor
Ernest Kissi Kontor
CWCatherine Wellan
Catherine Wellan
HMHafiz Mohammad Maaz
Hafiz Mohammad Maaz
DMDaha Garba Muhammad
Daha Garba Muhammad
Almonzer Al-QiamiAlmonzer Al-Qiami
Almonzer Al-Qiami
Nityanand JainNityanand Jain
Nityanand Jain
Background: Neuropathic pain (NP) is a chronic condition caused by abnormal neuronal excitability in the nervous system. Current treatments for NP are often ineffective or poorly tolerated. Hence, we reviewed the efficacy and safety of novel drugs or devices that target neuronal excitability in NP patients compared with placebo, sham, or usual care interventions.Methods: Six databases were searched for parallel randomized controlled trials (RCTs) reporting novel devices (rTMS, SCS, and TENS) or drugs (EMA401, capsaicin 8% patch, and Sativex) for NP. Data were extracted and quality was assessed using the ROB2 tool. The random‐effects inverse variance method was used for analysis.Results: In our review of 30 RCTs with 4251 participants, device‐based interventions were found to be more effective in reducing pain scores than control interventions (SMD = −1.27, 95% CI: −1.92 to −0.62). However, high heterogeneity was seen (p < 0.01, I2 = 91%), attributable to the etiology of NP (R2 = 58.84%) and year of publication (R2 = 49.49%). Funding source and type of control comparator were ruled out as cause of heterogeneity. Although drug interventions did not differ from placebo interventions in absolute pain reduction (SMD = −1.21, 95% CI: −3.55 to 1.13), when comparing relative change in pain intensity from baseline, drug interventions were found to be effective (SMD = 0.29, 95% CI: 0.04–0.55). Asymmetry in the funnel plot was visualized, suggesting publication bias. Certainty of evidence was very low according to GRADE assessment.Conclusions: Our review indicates that device‐based interventions are more effective than control interventions in reducing pain intensity in NP. Nevertheless, available evidence is limited due to heterogeneity and publication bias, prompting the need for more high‐quality RCTs to confirm the efficacy and safety of these interventions.

14 June 2025 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
AHAli Hammed
Ali Hammed
Almonzer Al-QiamiAlmonzer Al-Qiami
Almonzer Al-Qiami
AHAli Hasan
Ali Hasan
GRGregor Richter
Gregor Richter
AAAsmaa Zakria Alnajjar
Asmaa Zakria Alnajjar
CTChristian Tanislav
Christian Tanislav
Background: There is currently no established standard of care for recurrent glioblastoma (GBM). Re-irradiation (re-RT) and Bevacizumab (BEV) are both used in salvage treatment, but their combined efficacy remains uncertain. Objectives: To evaluate whether combining re-irradiation with BEV improves survival outcomes compared to BEV alone in patients with recurrent high-grade gliomas (rHGG). Design: Systematic review and meta-analysis of two-arm clinical trials. Data sources and methods: A comprehensive literature search was conducted in Scopus, PubMed, Web of Science, and the Cochrane Library up to April 2024. Two independent reviewers assessed studies for eligibility and extracted data. Study quality was evaluated using the ROBINS-I and ROBINS-II tools. The primary outcome was overall survival (OS); secondary outcomes included progression-free survival (PFS), toxicity, and prognostic factors. Results: The meta-analysis demonstrated a significant improvement in OS with combined BEV and re-irradiation compared to BEV alone (hazard ratio (HR) 0.69, 95% confidence interval (CI: 0.56–0.85); p = 0.0005), corresponding to a 31% reduction in the risk of death. PFS also improved significantly (HR 0.64, 95% CI (0.45–0.90); p = 0.01). No significant increase in grade 3 toxicities was observed with the combination therapy. Subgroup analyses indicated that younger age and female gender were statistically associated with better OS, though the effect of age was modest and male gender was linked to poorer survival. Karnofsky performance status significantly influenced survival. Pulsed versus non-pulsed re-irradiation showed no differential effect on outcomes. Conclusion: The combination of re-irradiation and BEV significantly improves both OS and PFS in patients with rHGG, without increasing severe toxicity. These findings support the safety and efficacy of the combined approach. Prospective trials are warranted to guide standardized treatment protocols. Trial registration: This review was prospectively registered with PROSPERO (CRD42023463183).

1 January 2024 in Sage Open Medicine
Verified
Journal Article
Open access
ERElena Cecilia Rosca
Elena Cecilia Rosca
Almonzer Al-QiamiAlmonzer Al-Qiami
Almonzer Al-Qiami
ACAmalia Cornea
Amalia Cornea
MSMihaela Simu
Mihaela Simu
Objective: Subarachnoid hemorrhage has high mortality and substantial long-term morbidity. Although SARS-CoV-2 infection is associated with hypercoagulopathy, patients may also present subarachnoid hemorrhage. We aimed to synthesize the clinical and paraclinical characteristics, treatment responses, and outcomes of this neurologic complication. Methods: The population included adults and children, and studies investigated patients with subarachnoid hemorrhagein the context of SARS-CoV-2 infection. We included prospective, retrospective, observational, or interventional studies. We systematically reviewed LitCOVID and the COVID-19 WHO database until February 2023, following a published protocol. Results are presented in tabular form to provide a descriptive summary of the findings. Results: We included 107 patients (30 aneurysmal SAH—aSAH, 52 non-aSAH confirmed by vascular imaging, and 25 without vascular imaging). Subarachnoid hemorrhage was concomitant or developed a few weeks after infection. Severity of COVID-19 ranged from asymptomatic (27.8% aSAH, 5.5% non-aSAH) to severe (50% aSAH, 75% non-aSAH). Patients presented inflammatory markers (25% aSAH, 81%non-aSAH), thrombocytopenia (12.5% aSAH, 28.6% non-aSAH), and impaired coagulation (0% aSAH, 28.6% non-aSAH). SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) in the cerebrospinal fluid was negative in seven patients. Brain samples were positive for SARS-CoV-2 in one case. Conclusions: An inadequate infection response may change aneurysmal size and morphology, with rupture tendency. Renine–angiotensine–aldosteron system disruption with hypertension and cough increases pressure on aneurysmal walls. Furthermore, mycotic and dissecting aneurysms were reported. Non-aSAH accompanies infection-related complications such as cerebral venous sinus thrombosis, reversible cerebral vasoconstriction syndrome, posterior reversible encephalopathy syndrome, or intracerebral hemorrhage. Cytokine release syndrome, endothelial dysfunction, and SARS-CoV-2 affinity for angiotensin-converting enzyme 2 receptors may induce vasculitic processes. Cough precipitates arterial dissection. Hypoxic brain injury, immune thrombocytopenia, and some COVID-19 medications increase bleeding risks.

10 April 2026 in Neurological Sciences
Verified
Journal Article
Closed access
AAAhmed W. Abbas
Ahmed W. Abbas
Almonzer Al-QiamiAlmonzer Al-Qiami
Almonzer Al-Qiami
KSKhalid Sarhan
Khalid Sarhan
AAAhmed Mohamed Abozaid
Ahmed Mohamed Abozaid
HMHamdy A. Makhlouf
Hamdy A. Makhlouf
Ahmed NegidaAhmed Negida
Ahmed Negida